🇺🇸·2h agoIndustry
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Publisher
A
AbbVie News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- AbbVie News
- Region
- USA
- Scope
- Industry
- Published
- July 24, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.abbvie.com
Leave the platform to read the original full article on the publisher site.
Source: AbbVie News
Scope: Industry
Related coverage
More related coverage
Certara/2h ago
Important drug development questions that model-based meta-analysis answers
Interpharma Switzerland/4h ago
3 Fragen an Adrian Cuadra Leon, General Manager von UCB ALPS (Austria & Switzerland)
Codexis/2h ago
Codexis Announces Proposed Public Offering of Common Stock
eXoZymes/2h ago